Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Biocatalytic Reduction. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN103255183B details enzymatic synthesis of S-CHBE. High purity and yield offer supply chain stability and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN104846025A details enzymatic synthesis of chiral intermediates. Offers cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN107794282B reveals a high-yield biocatalytic route for Crizotinib intermediates using Geotrichum candidum, offering superior purity and cost efficiency for API manufacturing.
Patent CN102925500A enables high-purity chiral ester synthesis via yeast biocatalysis, offering cost-effective and scalable pharmaceutical intermediate solutions for global supply chains.
Patent CN104232696A reveals biocatalytic method for high-purity chiral alcohol. Offers cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN105985990B details a green enzymatic route for phenylephrine intermediates using KRED and antioxidants, offering significant cost reduction in API manufacturing.
Patent CN112176019B details a high-yield biocatalytic route for (R)-1-(3-trifluoromethylphenyl) ethanol using recombinant E. coli and deep eutectic solvents, ensuring >99.9% e.e. and scalable production for neuroprotective intermediates.
Patent CN105087664A reveals high-yield biocatalytic route for chiral intermediates ensuring supply chain stability and significant cost efficiency for global pharmaceutical manufacturing partners seeking reliable production.
Patent CN106520856A enables high-concentration enzymatic reduction for pharmaceutical intermediates. Achieve superior purity and scalable supply chain reliability.
Patent CN103773724B reveals biocatalytic route for high-purity chiral alcohol. Enhances supply chain reliability and reduces manufacturing costs significantly.
Patent CN105039436A details biocatalytic synthesis offering high yield and purity. This method ensures supply chain stability and cost efficiency for global pharmaceutical manufacturing partners.
Patent CN101469318A enables high-purity (R)-phenylethylene glycol via dual-enzyme coupling, offering cost reduction and supply chain reliability for pharmaceutical manufacturing.
Novel enzymatic route for 4-AA intermediate reduces costs and improves purity for penem antibiotic manufacturing supply chains globally.
Patent CN102102087B details a novel Leifsonia xyli strain for producing key Aprepitant intermediates with superior yield and optical purity, offering significant supply chain advantages.
Patent CN104328147A details a novel biocatalytic route for chiral esters offering high purity and scalable manufacturing solutions for global supply chains.
Patent CN115011573B enables efficient synthesis of chiral alcohols with high substrate loading and reduced cofactor costs for pharmaceutical supply chains.
Patent CN104152506B reveals a crude enzyme system for high-purity pharmaceutical intermediates. This method offers significant supply chain and cost advantages for global buyers.
Patent CN104651425A enables high-purity lactone production with reduced costs and enhanced supply chain reliability for flavor manufacturers globally.
Patent CN106083811A details enzymatic synthesis for high purity. Offers cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN119119158B reveals a novel plant-derived synthesis route for ursodeoxycholic acid offering significant supply chain stability and cost reduction advantages.